Collectively, the results of both in vitro as well as antigen-specific pSTAT5 assays have shown higher responses to stimulation in the FOXP3+ subset, which was characterized by significantly higher levels of basal pSTAT5 relative to Tcon cells in patients with advanced CLL treated with CIT. The gene discussed is FOXP3; the disease is B-cell chronic lymphocytic leukemia.